In a report released yesterday, Benjamin Burnett from Stifel Nicolaus downgraded Global Blood Therapeutics (GBT – Research Report) to a Hold, with a price target of $68.50. The company’s shares closed yesterday at $66.57.
According to TipRanks, Burnett is an analyst with an average return of -8.4% and a 33.33% success rate. Burnett covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, CTI BioPharma, and Atara Biotherapeutics.
In addition to Stifel Nicolaus, Global Blood Therapeutics also received a Hold from SVB Securities’s Andrew Berens in a report issued on August 9. However, on August 8, Canaccord Genuity upgraded Global Blood Therapeutics (NASDAQ: GBT) to a Buy.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $73.02 and a one-year low of $21.65. Currently, Global Blood Therapeutics has an average volume of 2.51M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
Read More on GBT:
- Stifel Nicolaus Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
- Karuna Therapeutics (KRTX) Gets a Buy from Stifel Nicolaus
- Stifel Nicolaus Sticks to Its Buy Rating for Power Integrations (POWI)
- Stifel Nicolaus Sticks to Its Hold Rating for Kornit Digital (KRNT)
- Stifel Nicolaus Keeps Their Hold Rating on Watts Water Technologies (WTS)
